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-Defensins are known to be both antimicrobial and able to chemoattract various immune cells. Although
the sequences of paralogous genes are not highly conserved, the core defensin structure is retained. Defb14-1CV
has bactericidal activity similar to that of its parent peptide (murine -defensin Defb14) despite all but one of
the canonical six cysteines being replaced with alanines. The 23-amino-acid N-terminal half of Defb14-1CV is
a potent antimicrobial while the C-terminal half is not. Here, we use a library of peptide derivatives to
demonstrate that the antimicrobial activity can be localized to a particular region. Overlapping fragments of
the N-terminal region were tested for their ability to kill Gram-positive and Gram-negative bacteria. We
demonstrate that the most N-terminal fragments (amino acids 1 to 10 and 6 to 17) are potent antimicrobials
against Gram-negative bacteria whereas fragments based on sequence more C terminal than amino acid 13
have very poor activity against both Gram-positive and -negative types. We further test a series of N-terminal
deletion peptides in both their monomeric and dimeric forms. We find that bactericidal activity is lost against
both Gram types as the deletion region increases, with the point at which this occurs varying between bacterial
strains. The dimeric form of the peptides is more resistant to the peptide deletions, but this is not due just to
increased charge. Our results indicate that the primary sequence, together with structure, is essential in the
bactericidal action of this -defensin derivative peptide and importantly identifies a short fragment from the
peptide that is a potent bactericide.
-Defensins are believed to be important components in
innate immunity. They are expressed predominantly at muco-
sal surfaces and the reproductive tract. They are a multigene
family which has 40 members spread over five genomic loci
in humans (18). They possess a strong, broad-spectrum anti-
microbial action in vitro and also have been shown to be che-
moattractants for various immune cells (23, 24). Some -de-
fensins are rapidly induced by exposure to lipopolysaccharide
or Th1 cytokines, while human -defensin 1 (hBD1) expres-
sion is mostly constitutive (14). Recently, increased copy num-
ber of the -defensins at the chromosome 8 locus has been
associated with an increased risk of psoriasis (7). Conversely,
decreased copy number of this cluster has been associated with
an increased risk of inflammatory bowel disease (5).
Defensins have a canonical six-cysteine motif, but the remain-
ing sequence of these short peptides is not highly conserved. The
consensus is X2-10CX5-7(G/A)XCX3-4CX9-13CX4-7CCXn, where
X is any residue, G/A is glycine or alanine, and C is cysteine. The
spacing and connectivity of the six cysteines separate -de-
fensins from -defensins, and although highly conserved
throughout evolution, the canonical six-cysteine motifs in ei-
ther defensin class are not required for antimicrobial activity
(2, 11, 20, 23). The canonical disulfide bridges may be impor-
tant for protection of the peptide in vivo, as has been demon-
strated for -defensins (11).
Evolutionary studies of the mouse and human genomes have
revealed that Defb14 is the mouse orthologue of human -de-
fensin 3 (DEFB103) (19). The peptide encoded by Defb14 has
salt-resistant, wide-range antimicrobial activity very similar to
that of the peptide encoded by DEFB103 (human -defensin
3-hBD3) (6, 16, 20). Like all defensins, hBD3 has an antipar-
allel -sheet scaffold with a short N-terminal -helix (17), and
this structure is conserved throughout evolution.
Given the promiscuity of the endogenous peptides, under-
standing the structure-activity relationships of -defensins is
essential. Work in this area aims to find key information for
designing novel synthetic antibiotics and for clarifying their
function in immunity. There is some controversy as to the
mode of action of defensins with membrane disruption by
some mechanism seeming to occur. However, studies with
hBD3 in Staphylococcus aureus have revealed the occurrence
of rapid killing and at the same time blockage of all biosyn-
thetic pathways, although significant depolarization of the bac-
terial membranes was not observed and permeabilization was
incomplete (1).
Wu et al. (23) elegantly used directional disulfide bonding to
demonstrate that the disulfide connectivities influenced the
chemoattractant potency of hBD3 but not the antibacterial
effect. We have also shown that hBD3 or Defb14 peptides with
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all but one cysteine being replaced by alanine were still active
as both a chemoattractant and an antimicrobial. The remaining
cysteine was at position V of the canonical six-cysteine motif
(-CI-CII-CIII-CIV-CV-CVI-), where the cysteines are inter-
spersed with a variable number of amino acid residues. Hoover
et al. (8) demonstrated that peptides from the C-terminal re-
gion of hBD3 had potent activity against Escherichia coli and
Pseudomonas aeruginosa but not S. aureus. The shortest pep-
tide was a decapeptide based on sequence from the C-terminal
end of the molecule (RGRKSSRRKK). The two adjacent cys-
teines in the native peptide were replaced with serines to
eliminate the potential to form disulfide bonds (8). Further
work using modifications of this decapeptide sequence has
shown that its antimicrobial activity is more complex than just
being a function of charge (13). In addition, work on an hBD3
derivative where the cysteines of the full-length mature peptide
are changed to alanines has revealed that this peptide is as
active as the parent peptide against Gram-positive and -nega-
tive bacteria but is now sensitive to the ionic strength of the
medium (3). As the cysteine content of the peptide does not
affect the antimicrobial activity of the peptide, we have focused
on the Defb14-1CV analogue (20). This peptide has all the
cysteines replaced with alanines except Cys40, which resides at
position V of the six-cysteine motif. In addition, it can easily be
controlled to form monomer or dimer species. We have pre-
viously shown that this peptide analogue has the same salt-
insensitive bactericidal activity as the parent Defb14 peptide
(20). In addition, we divided the active Defb14-1CV peptide
into an N-terminal and a C-terminal fragment and found that
the C-terminal half (residues 24 to 45) was a very poor anti-
microbial compared to the N-terminal fragment (residues 1 to
23), which was potent. In order to further dissect the residues
important for the antimicrobial activity of Defb14-1CV, we
created a library of peptide fragments. We show that the an-
timicrobial activity of the most N-terminal residues is most
potent, and deletion of these residues reveals that the points at
which the activity is most significantly lost vary for different
bacterial strains. We conclude that both the sequence and
structure that a given sequence imposes are important for
antimicrobial activity.
MATERIALS AND METHODS
Peptide synthesis and purification. All peptides were chemically synthesized
by standard solid-phase methodology. Defb14 and Defb14-1CV were obtained
from Chemical Synthesis Services-Albachem Ltd. (Gladsmuir, United King-
dom). Disulfide connectivities were determined by proteolysis and peptide mass
mapping by following the procedures outlined by Campopiano et al. (2). The
sequences are shown in Table 1. The defensin 14-inspired peptides, including
additional synthesis of Defb14-1CV, were made in-house using automated pep-
tide synthesis. This was carried out on an Applied Biosystems model 433A
peptide synthesizer using Rink amide-AM resin for peptide amides, preloaded
NovaSyn TGT resin for peptide acids, and 9-fluorenylmethoxy carbonyl (Fmoc)
amino acids, all from Novabiochem. All truncated Defb14-1CV peptides were
synthesized with an acetyl group at the N terminus, rather than the free amino
group, to best represent the conformation of the terminal amino acid. Liquid
chromatography (LC) mass spectra confirming identity and purity were obtained
on a Micromass Quattro LC mass spectrometer. Semipreparative high-perfor-
mance liquid chromatography (HPLC) was performed using a Phenomenex
Luna C18 column and a gradient of 5 to 95% acetonitrile (containing 0.1%
trifluoroacetic acid) over 45 min (flow rate of 3.0 ml/min). All other chemical
reagents were obtained from Aldrich. Automated solid-phase peptide synthesis
was carried out on a 0.05-mmol scale using 0.5 mmol of each Fmoc amino acid
per coupling reaction and 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium
hexafluorophosphate/1-hydroxybenzotriazole as coupling reagents. Coupling
time was 0.5 h. Peptide products were cleaved from the resin with 95% triflu-
oroacetic acid, 2.5% ethanedithiol, and 2.5% water for 3 h, the resin was filtered
off and washed with trifluoroacetic acid, and filtrate was poured into diethyl ether
(10 volumes). Following centrifugation (3,000 rpm at 15 min), the precipitate was
resuspended in ether (5 volumes) and recentrifuged (3,000 rpm at 15 min). The
crude peptides were dissolved in water and loaded directly onto a semiprepara-
tive HPLC column. Peptide fractions were identified by mass spectrometry (MS)
and lyophilized.
Bactericidal assays. Bactericidal assays were carried out as previously de-
scribed (20). Briefly, test organisms were grown to mid-logarithmic phase in
Iso-Sensitest broth (Oxoid) growth medium and then diluted to between 1  106
CFU/ml and 5  106 CFU/ml in 10 mM potassium phosphate containing 1%
(vol/vol) Iso-Sensitest broth, pH 7.4. Different concentrations of test peptide
were incubated in 100 l of cells (1  105 to 5  105 CFU) at 37°C for 3 h.
Reduction of the peptides, where performed, was done by adding 10 mM di-
thiothreitol (DTT) and incubating the peptides at room temperature overnight.
The oxidation state of each peptide was determined by mass spectrometry.
Tenfold serial dilutions of the incubation mixture were spread on Iso-Sensitest
plates and incubated at 37°C, and the numbers of CFU were determined the
TABLE 1. Sequences of Defb14-derived peptides
Peptide Sequencea
Defb14 ...............................................................................................................................FLPKTLRKFFCRIRGGRCAVLNCLGKEEQIGRCSNSGRKCCRKKK
Defb14-1CV .......................................................................................................................FLPKTLRKFFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1) ............................................................................................................... LPKTLRKFFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1-2) ............................................................................................................ PKTLRKFFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1-5) ............................................................................................................ LRKFFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1-8) ............................................................................................................ FFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1-11).......................................................................................................... RIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1-14).......................................................................................................... GGRAAVLNALGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1-17).......................................................................................................... AAVLNALGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1-23).......................................................................................................... LGKEEQIGRASNSGRKCARKKK
Defb14-1CV(1-23).............................................................................................................FLPKTLRKFFARIRGGRAAVLNA
Defb14-1CV(1-10).............................................................................................................FLPKTLRKFF
Defb14-1CV(6-17)............................................................................................................. LRKFFARIRGGR
Defb14-1CV(18-23)........................................................................................................... AAVLNA
Defb14-1CV(14-23)........................................................................................................... RGGRAAVLNA
Defb14-1CV(12-23)........................................................................................................... RIRGGRAAVLNA
Defb14-1CV(13-34)........................................................................................................... IRGGRAAVLNALGKEEQIGRAS
a The sequences are given using single-letter abbreviations for amino acid residues; cysteine residues are in boldface. Deletion peptides are based on the Defb14-1CV
active peptide used previously (20).
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following day. The minimum bactericidal concentration (MBC) is the concen-
tration of peptide at which we observed 99.99% killing of the initial inoculum.
All assays were performed in duplicate and repeated on three independent
occasions. The minimum bactericidal concentration was obtained by taking the
mean of all of the results, and experimental errors were within one doubling
dilution. Significant differences between MBCs were determined using a Mann-
Whitney U test.
Molecular hydrophobicity analysis. The relative molecular hydrophobicity of
each monomeric peptide was evaluated by reverse-phase HPLC-MS using an
Ultimate 3000 LC system equipped with a Famos autosampler (Dionex) and a
VG Platform II mass spectrometer. A total of 30 l of each sample, containing
50 M peptide in 10 mM dithiothreitol (DTT) and 50 M melittin (Sigma) as an
internal standard, was injected onto a Waters Symmetry C18 column (3.9 by 150
mm). DTT was used to prevent dimerization of any of the peptides via cysteine
oxidation; this was confirmed by mass analysis following the LC separation.
Initial conditions were as follows: 100% eluent A (96% water, 3% acetonitrile,
1% formic acid); 0% eluent B (4% water, 95% acetonitrile, 1% formic acid); and
flow rate, 1 ml min1. Samples were eluted from the column by using a linear
gradient of 0 to 40% eluent B over 40 min. The flow was split 1/50 prior to
introduction to the electrospray ionization source of the mass spectrometer. In
order to assess the relative molecular hydrophobicities, we compared the reten-
tion time of each peptide to that of melittin.
G, the hydrophobicity score (kcal/mol) of monomeric peptides in water, was
calculated using the scale of Wimley and White (22), where greater hydropho-
bicity is indicated by a less negative value.
Helical wheel projections. Helical wheel projections were constructed with the
aid of the program at http://rzlab.ucr.edu/scripts/wheel/wheel.cgi.
RESULTS
Bactericidal activity of peptide fragments. In order to nar-
row the antibacterial activity of Defb14-1CV to a particular
region of the molecule, we synthesized three overlapping frag-
ments (1 to 10 [1-10], 6 to 17 [6-17], and 14 to 23 [14-23]) of the
antimicrobially active N-terminal Defb14-1CV. These frag-
ments (see Table 1 for sequences) were tested against a panel
of Gram-positive and Gram-negative bacteria. We determined
the minimum bactericidal concentration (MBC) values for
these peptide fragments (Table 2), i.e., the minimum concen-
tration at which less than 99.99% of the initial inoculum is
viable.
The 23-amino-acid N-terminal fragment Defb14-1CV(1-23)
has bactericidal activity very similar to that of Defb14-1CV (as
previously reported under the name D14ip 1 [20]) against
Pseudomonas aeruginosa PAO1 and S. aureus ATCC 25923.
The peptide fragment with the first 10 amino acids of Defb14-
1CV [Defb14-1CV(1-10)] shows good activity against P. aerugi-
nosa PAO1 (MBC of 1.0 M), Acinetobacter baumannii (MBC
of 0.58 M), and E. coli (MBC of 2.3 M), and these are within
one doubling dilution of the Defb14-1CV(1-23) fragment and
comparable to the parental peptide activity against these
strains. The Defb14-1CV peptide fragment with the 12 internal
amino acids [Defb14-1CV(6-17)] also has a strong bactericidal
activity against the three Gram-negative strains tested. The
peptide fragments containing amino acids 14 to 23 and 13 to 34
do not achieve an MBC against the bacteria at the concentra-
tions tested here. Interestingly, only one of the two most N-
terminal peptides has good activity against the Gram-positive
strains tested. Only the fragment with residues 6 to 17 has the
ability to kill all the Gram-positive strains at a concentration
less than 19 M (30 g/ml). Defb14-1CV(6-17) had good
activity against methicillin-resistant S. aureus (MRSA) strain
J2918 (MBC of 4.8 M), comparable with that of the Defb14-
1CV(1-23) fragment, and its MBC against S. aureus was 8.2
M. We previously reported that Defb14-1CV and the active
N-terminal fragment Defb14-1CV(1-23) had salt-insensitive
activity against P. aeruginosa (20). Interestingly, the bacteri-
cidal activities of both Defb14-1CV(1-10) and Defb14-1CV(6-
17) against P. aeruginosa are unchanged with increasing salt
concentrations of up to 200 mM NaCl (data not shown).
Bactericidal activity of N-terminal deletions. In order to
further dissect the antimicrobial sequence within the N-termi-
nal region of Defb14-1CV and in the context of the molecule
with the C-terminal region included, we made a series of N-
terminal deletions (see Table 1 for sequences). As the dele-
tions are based on Defb14-1CV, they all have a single cysteine
residue (CysV40). This enabled us to examine both monomeric
and covalent dimeric forms, with the latter occurring via a
disulfide bridge. Following oxidation, the peptides spontane-
ously form a homodimer through the cysteine-cysteine disul-
fide bridge and reduction with DTT leaves the peptide in the
reduced form, as verified by mass spectrometry, and this state
is maintained throughout the assay (data not shown). We de-
termined the MBCs of both the dimeric and monomeric mol-
ecules against three Gram-negative and three Gram-positive
bacterial strains for all the deletion peptides (Table 3).
As the deletions progress, the MBC increases in all cases,
TABLE 2. MBCs of Defb14-1CV derivatives against a range of Gram-negative and Gram-positive bacteria
Organism and strain
MBC (M) for peptidea:
Defb14 Defb14-1CV Defb14-1C
V
(1-23)
Defb14-1CV
(1-23)
Defb14-1CV
(1-10)
Defb14-1CV
(6-17)
Defb14-1CV
(14-23)
Defb14-1CV
(13-34)
Gram negative
P. aeruginosa PAO1 0.3 0.3 0.6 20.5 1.2 1 48 22
A. baumannii ATCC 19606 0.6 0.6 1.2 20.5 19 1 48 22
Burkholderia cenocepacia J2315 20 20 20 20.5 40 33 48 22
E. coli ATCC 25922 0.6 0.6 1.2 20.5 9.6 2 48 22
Gram positive
E. faecalis ATCC 700802 1.2 1.2 2.4 20.5 19 16.5 48 22
S. aureus ATCC 25923 0.6 0.6 1.2 20.5 38.6 9.6 48 22
MRSA J2918 1.2 1.2 2.4 20.5 38.6 4.8 48 22
a Bactericidal activity is located in the N-terminal sequence of the -defensin peptide. The region of the molecule that the peptide sequence is derived from is
indicated beneath its name by gray shading. Boldface indicates MBC of less than 20 M.
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indicating loss of bactericidal activity. The points at which the
bactericidal activity significantly reduces are not the same for
all the bacterial strains. Deletion of 14 amino acids results in
the monomeric form of the peptide being unable to kill any of
the six bacterial strains at the concentrations tested. The crit-
ical point for activity against P. aeruginosa and A. baumannii
ATCC 19606 is between Defb14-1CV(1-11) and Defb14-
1CV(1-14). However, against another Gram-negative strain
(E. coli), deletion of 8 amino acids results in the bactericidal
activity falling 4-fold to 10 M (37.3 g/ml). Against Gram-
positive S. aureus ATCC 25923 and MRSA J2918, the bacte-
ricidal activities drop significantly after deletion of 11 amino
acids. However, deletion of only 5 amino acids results in the
monomeric peptide significantly losing activity against Entero-
coccus faecalis.
The dimeric peptides are more robust than the monomers in
their ability to kill the bacteria when the N-terminal amino
acids are progressively deleted. All four strains tested show a
significant increase in the MBC of the monomeric species
before the dimeric species’ MBC is affected. P. aeruginosa is
killed at only 1.4 M with the Defb14-1CV(1-14) dimeric
species, whereas the monomeric form is not able to kill the
bacterium at 16.5 M. The same effect was observed with E.
coli and A. baumannii, where the monomer species loses bac-
tericidal activity before the dimer forms. The Gram-positive
strains also display this effect. For Defb14-1CV(1-11), there is
a 6-fold increase in the amount of monomer required to kill S.
aureus ATCC 25923 compared to the amount of dimer (5.9
M versus 0.9 M), and with the same peptide, the monomer
MBC against MRSA is 10 M, compared to 1.5 M for the
dimer MBC.
The dimer deletion peptide activities against P. aeruginosa in
increasing sodium chloride concentrations of up to 200 mM
were tested. Like the parent peptide and peptide fragments 1
to 10 and 6 to 17, the bactericidal activities of deletion peptides
up to and including Defb14-1CV(1-5) were not significantly
affected by addition of sodium chloride at concentrations of up
to 200 mM. However, deletion peptide Defb14-1CV(1-8) had
a significantly (P 	 0.01) raised MBC of 10 (
0.0) M in 10
mM sodium chloride compared to 1.7 (
0.0) M in 0 mM
NaCl. The subsequent deletions also showed significantly (P 	
0.01) increased MBCs of10 mM in 100 mM NaCl, indicating
that loss of the N-terminal region of Defb14-1CV rendered
these peptides salt sensitive.
In order to check whether degradation of the peptides by
bacterium-specific proteases could explain the loss of bacteri-
cidal activity, the integrity of the inactive peptide Defb14-
1CV(1-14) was evaluated by LC-MS following incubation
with S. aureus ATCC 25923. After 4 h, the majority of the
peptide remained intact (peak area of 66% relative to that of
sample prior to incubation; data not shown), indicating that
proteolysis of the peptide by the bacterial strain does not
explain its inactivity.
Charge versus bactericidal activity. In an effort to determine
whether charge rather than the primary sequence of the pep-
tides had an effect on the ability to kill bacteria, we considered
the net charge of each sequence in the peptide library we had
synthesized. Figure 1 shows the charge of monomer molecules
(and dimer molecules where relevant) and is annotated ac-
cording to which peptides are active against P. aeruginosa
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PAO1 with an MBC of less than 5.0 M (shown as filled dots
or squares in the figure). All the inactive peptides (shown with
open dots or squares) possess a charge of less than 11; how-
ever, six active peptides also have a charge of less than 11,
with Defb14-1CV(1-10) having a charge of only 5 and an
MBC of 1.2 M. The Defb14-1CV(1-17) dimer has a charge
of 10 and is a potent antimicrobial agent with a low MBC,
but in contrast, the Defb14-1CV(1-23) dimer has an equal
charge but is an inactive antimicrobial with an MBC in excess
of 10 M.
Hydrophobicity versus bactericidal activity. We also as-
sessed the hydrophobicity of the deletion peptides both ac-
cording to their primary sequences via the Wimley-White scale
for proteins at a membrane interface (Fig. 2a) (22) and exper-
imentally by measuring their retention times by reverse-phase
HPLC (Fig. 2b). This second method is sensitive to the con-
formation of the free peptide in solution. However, we observe
little difference between the hydrophobicities of these pep-
tides, as gauged by either method (Fig. 2). The hydrophobicity
via HPLC does decrease as the length of the peptide decreases,
with the exception of Defb14-1CV(1-17), which shows a slight
increase relative to that of Defb14-1CV(1-14). The observed
differences in bactericidal activity with these peptides cannot
be attributed to any dramatic difference in the hydrophobicity
of the free peptide.
Structural change as determined by helical wheel projec-
tion. Figure 3 shows a helical wheel projection of Defb14-1CV
(residues 1 to 18) which predicts that the N-terminal region of
the full-length peptide has the potential to form an -helix with
charged residues concentrated on one face of the helix and
hydrophobic residues on the other. The distinction between
hydrophilic and hydrophobic faces is less clear in helical wheel
projections of residues 12 to 29 and 15 to 32, which correspond
to the N-terminal regions of the Defb14-1CV(1-11) and
Defb14-1CV(1-14) peptides, respectively. This suggests a
lesser propensity to form an -helix, which we have also shown
by circular dichroism (CD) (21), and may account, in part, for
the diminished activity of the truncated peptides. There is little
difference in these projections for residues 12 to 29 and 15
to 32.
DISCUSSION
In order to further dissect the basis of the potent bactericidal
activity of the N-terminal region of the Defb14-1CV derivative,
we synthesized several overlapping fragments of the 23-amino-
acid region and a series of Defb14-1CV-derived peptides with
progressive N-terminal deletions. We determined their MBCs
against a panel of Gram-positive and -negative bacterial strains.
Although the Defb14-1CV(6-17) fragment is a strong bactericide,
the deletion series reveals that there does not appear to be one
short sequence responsible for activity against all strains.
Primary sequence determines bactericidal activity against
different bacteria. We show that the more C-terminal fragment
FIG. 1. Charge and structure are important for antimicrobial ac-
tivity of -defensin derivatives. The Defb14-1CV derivative library was
plotted according to the net charge (protonation state) of the synthe-
sized peptides at a neutral pH. This takes into account the number of
basic versus acidic amino acids and also the termini. The key indicates
whether peptides are active bactericides and dimers or monomers.
FIG. 2. Assessment of the relative hydrophobicities of the Defb14-
1CV N-terminal deletion series. (a) The retention times of each N-
terminal deletion peptide, relative to that of melittin, are measured for
both the monomer and dimer under reducing and nonreducing con-
ditions, respectively. Increased relative retention time is indicative of
more hydrophobic character, since under a reversed-phase gradient
hydrophobic peptides will be retained longer on the C18 column. For
comparison, panel b shows the theoretical hydrophobicity score (in
kcal mol1) of each peptide in water, calculated using the scale of
Wimley and White (22). Greater hydrophobicity is indicated by a less
negative value.
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Defb14-1CV(14-23) has very poor activity against both Gram-
positive and -negative strains, whereas Defb14-1CV(1-10) and
Defb14-1CV(6-17) retain some aspects of the antibacterial
activity of the parent molecule. Both fragments are potent
bactericides against the three Gram-negative strains tested;
however, only Defb14-1CV(6-17) is robust against the Gram-
positive S. aureus strains. The deletion series allowed us to
determine whether these fragments influence bactericidal ac-
tivity within the context of the full-length molecule. We find
that as the N-terminal deletions progress, the monomeric pep-
tide MBC increases (indicating loss of activity), but the points
at which significant MBC increase occurs vary between strains.
The deletion series indicates that the critical amino acid resi-
dues required for bactericidal activity are located between res-
idues 5 and 14 (concordant with the activity of fragments 1 to
10 and 6 to 17). Gram-positive strains MRSA J2918 and S.
aureus ATCC 25923 are effectively killed by Defb14-1CV(6-
17) but not Defb14-1CV(1-10). In agreement with this, the
ability of the truncated peptides to kill S. aureus ATCC 25923
and MRSA J2918 reduces significantly with the deletion of
residues 9, 10, and 11 (FFA). The charge of active Defb14-
1CV(1-8) is the same (8) as that of poorly active
Defb141CV(1-11), with little change in hydrophobicity, sug-
gesting that the difference in activity is indeed primarily se-
quence/structure based. This contrasts with work on hBD3,
where charge and hydrophobicity have been found to influence
antimicrobial activity (9).
Although amino acid residues 9 to 11 appear to be important
in the killing of Gram-positive S. aureus strains, deletion of
these residues results in little change to the monomeric MBC
against Gram-negative P. aeruginosa PAO1 and A. baumannii.
However, the subsequent deletion of RIR in Defb14-1CV(1-
14) results in a significant loss of activity. This decrease in
sensitivity is not wholly dependent on the Gram status of the
bacteria, since Gram-negative E. coli ATCC 25922 shows sen-
sitivity to Defb14-1CV(1-11) in a pattern similar to that of
Gram-positive S. aureus species.
These data again suggest that the primary amino acid se-
quence is important for bactericidal activity. This notion is
supported by a similar study with hBD1 which revealed that
antimicrobial activity against E. coli was affected mostly by
amino acid substitutions of charged residues in the positively
charged C-terminal region (15). These substitutions did not
affect peptide topology, and the study concluded that it was the
side chain changes that affected the antibacterial activity. Re-
cently, it was reported that the bactericidal activity of -defen-
sin cryptdin 4 was attenuated when all the arginines were
mutated to lysine. Llenado et al. (10) postulate that the gua-
nidine group in arginine may allow stronger electrostatic
charges and hydrogen bonding interactions, which may be im-
portant for electronegative bacterial cell membrane interac-
tions. However, we have tested whether inclusion of the RIR
sequence results in a peptide with bactericidal activity, but
peptide Defb14-1CV(12-23) with sequence RIRGGRAA
VLNA is inactive as a bactericide at 20 M against both P.
aeruginosa and S. aureus (data not shown).
Multiple sequences contribute to bactericidal activity. E.
coli, P. aeruginosa PAO1, and A. baumannii are killed effec-
tively by peptide fragments Defb14-1CV(1-10) and Defb14-
1CV(6-17). The deletion series monomer data support both of
these fragments containing unique sequence that is important
in the context of the peptide. Sequential deletion of amino
acids 6, 7, and 8 and then 9, 10, and 11 (E. coli) and amino
acids 9, 10, and 11 followed by 12, 13, and 14 (P. aeruginosa)
results in an individual decrease in bactericidal potency. This
suggests that there are two regions important to bactericidal
activity, one in Defb14-1CV1-10 and one in Defb14-1CV6-17,
so that only when both are deleted from the larger molecule is
the activity very much reduced.
Supporting this is our previous finding that the sequence
NTLQK in hBD3 (corresponding to KTLRK in Defb14) has
been subjected to negative selection during primate evolution
(19). This sequence is contained fully in Defb141CV(1-10) and
partially in Defb141CV(6-17), suggesting that the region is
important functionally. Interestingly, it is also this region
(LRK) that appears to be critical in maintaining the salt in-
sensitivity of the peptides against P. aeruginosa.
FIG. 3. Helical wheel projections of N-terminal regions of Defb14-1CV and inactive/active derivatives. Schematic helical wheel projections of
Defb14-1CV (residues 1 to 18) (A), Defb14-1CV(1-11) (residues 12 to 29) (B), and Defb14-1CV(1-14) (residues 15 to 32) (C). Charged residues
are denoted by white circles. Increasing hydrophobicity is denoted by increasing shading. The positions of the side chains are shown along a
“regular” -helix. For a right-handed helix with 3.6 residues per turn, rotation is clockwise as the polypeptide chain is followed from N to C, and
the 5th residue ends up in a position exactly 40° clockwise relative to that of residue 1.
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Dimeric structure retains activity. The bactericidal activity
of the dimeric deletion peptides is more resistant to the dele-
tion of amino acids than that of the monomeric forms up until
the Defb14-1CV(1-14) fragment (against S. aureus) and de-
letion of RIR. This indicates that dimer structure, in addition
to sequence, is important for bactericidal activity. The in-
creased charge of dimeric molecules may implicate charge as a
contributor to antibacterial activity; however, the inactivity of
dimeric Defb14-1CV(1-14) implies that sequence and struc-
ture are more important than charge for this strain. In order to
consider this further, we compare the charges and bactericidal
activities for the various peptides against P. aeruginosa PAO1
(Fig. 1). Comparison of bactericidal activities between Defb14-
1CV(1-23) and Defb14-1CV(1-17) dimers with the same
charge (5) and similar low hydrophobicities but vastly differ-
ent bactericidal activities supports that sequence and structure
are more important than charge.
The importance of dimeric structure is further supported by
evidence that covalent dimeric defensins are more active bac-
tericides than monomeric or noncovalent dimers (2, 4) and by
the recent report by Antcheva et al. (1) which demonstrated
that covalent dimerization of an artificial defensin could im-
prove its antimicrobial activity.
Helical structure may affect function. We performed circu-
lar dichroism (CD) on an analogue of Defb14-1CV(1-23),
which has poor antimicrobial activity identical to that of
Defb14-1CV(1-23) but alanines at all the cysteine positions
(20). When compared to the potent N-terminal peptide
Defb14-1CV(1-23), it is shown to have reduced helical propen-
sity (21; data not shown). We also show by helical wheel pro-
jection that the helix-forming propensity of the N-terminal
region is likely to be lost as the peptide deletions increase. This
may be important since the formation of helical oligomers is
implicated in the pore model of antimicrobial action. However,
there is little difference in these projections for residues 12 to
29 and 15 to 32 to rationalize the lack of bactericidal activity
against P. aeruginosa of the Defb14-1CV(1-14) monomer rel-
ative to that of Defb14-1CV(1-11). In addition, the activities
found in these deletion peptides and mode of action may not
reflect those present in the full-length disulfide stabilize mol-
ecule.
Of the peptides tested here, Defb14-1CV(6-17) has the most
potential as a short and effective bactericidal agent in vitro. We
have, however, found that the bactericidal activities of the
peptide fragments and parental -defensin are inhibited by
serum, although not by trypsin digestion (data not shown),
which is also observed for hBD3 (12).
In conclusion, our results show that both structure and se-
quence are important for the antimicrobial activity of these
-defensin derivatives. We find that the activities of the N-
terminal peptide fragments are supported by the N-terminal
deletions, and we find that the precise sequences that confer
bactericidal activity vary for different bacteria, showing selec-
tivity at the amino acid level. We have shown that deletion of
FFA and RIR is important for loss of activity against S. aureus,
deletion of LRK for E. coli and E. faecalis, and deletion of RIR
for P. aeruginosa and A. baumannii. We also show that, in all
cases, covalent dimer peptides retain activity better than mo-
nomeric forms. Approaches aimed at determining the molec-
ular basis of structure-activity relationships will greatly assist in
the design of novel therapeutic agents.
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